FindTrial
Sign In

BIOLOGICALS SUPPORTS STUDY IN RESECTIVE SURGERY OF PANCREATIC - ND

BIOLOGICALS SUPPORTS STUDY IN RESECTIVE SURGERY OF PANCREATIC - ND

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2008-005714-46-IT
Enrollment
Unknown
Registered
2009-01-07
Start date
2009-02-10
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PANCREATIC DISEASE

Interventions

Trade Name: TACHOSIL Pharmaceutical Form: Sealant INN or Proposed INN: FIBRINOGENO UMANO Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5.5- INN or Proposed INN: T

Sponsors

ISTITUTO CLINICO HUMANITAS
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: AGE > 18 - LAPAROTOMIC OR LAPAROSCOPIC SURGERY - PANCREATIC DISEASE AND RESECTIVE SURGERY Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: OTHER PANCREATIC RESECTION - CRONIC PANCREATITIS

Design outcomes

Primary

MeasureTime frame
Main Objective: APPEARANCE OF PANCREATIC FISTULA;Secondary Objective: AMILASY LEVELS - DURATION OF SURGERY - DURATION OF OSPEDALISATION;Primary end point(s): APPEARANCE FISTULA PANCREATIC—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026